Detection of Erythropoietin in Exhaled Breath Condensate of Nonhypoxic Subjects Using a Multiplex Bead Array

Schümann, Christian; Triantafilou, Kathy; Krueger, Stefan; Hombach, Vinzenz; Triantafilou, Martha; Becher, G; Lepper, Philipp M.

doi:10.1155/mi/2006/18061

Cited by 28 publications

(20 citation statements)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall level of detection was 46-97%, which was much better compared with cytometric bead array in small samples in children (,50%), and in large 1,000-2,000-mL lyophilisated samples in adults (3-100%) [6,[23][24][25][26]. When compared with conventional (solid-phase) immunoassays, multiplexed immunoassays detect bioactive and inactive molecules, have a growing analytical range, are rapid (take hours instead of days to perform), have good precision (CV 10-15%), are not interfered with by drugs, and have simple protocols [7].…”

Section: Discussionmentioning

confidence: 93%

Biomarker reproducibility in exhaled breath condensate collected with different condensers

Rosias¹,

Robroeks²,

Kester³

et al. 2008

European Respiratory Journal

View full text Add to dashboard Cite

Optimal collection and analysis of exhaled breath condensate (EBC) are prerequisites for standardisation and reproducibility of assessments. The present study aimed to assess reproducibility of EBC volume, hydrogen peroxide (H 2 O 2 ), 8-isoprostane and cytokine measurements using different condensers, including a newly developed glass condenser.At four points in time, 30 healthy subjects performed sequential EBC collections randomly using the following four condensers: glass, silicone, EcoScreen1 (Erich Jaeger GmbH, Hoechberg, Germany) and an optimised glass condenser. In small EBC samples, H 2 O 2 was measured by spectrophotometer, 8-isoprostane by enzyme immunoassay, and cytokines by multiplexed xMAP1 technology (Luminex Corporation, Austin, TX, USA).The optimised glass condenser yielded significantly more EBC volume (median 2,025 mL, interquartile range 1,600-2,525). The reproducibility of EBC volume, yielded by the new glass condenser, was comparable with EcoScreen1 (19-20 coefficients of variation (CV)%), but was significantly better compared with silicone and glass (29-37 CV%). The new condenser was associated with significantly more detections of H 2 O 2 , 8-isoprostane, interleukin-2, -4, -5 and -13, and tumour necrosis factor-a. Isoprostane concentrations were significantly higher using the new condenser, whereas H 2 O 2 and cytokine concentrations were not. Reproducibility of biomarkers was equally variable for all condenser types.In conclusion, significantly more exhaled breath condensate volume and biomarker detections were found using the optimised glass condenser, including higher 8-isoprostane levels. However, biomarker reproducibility in exhaled breath condensate in healthy adults was not influenced by the type of condenser.

show abstract

Section: Discussionmentioning

confidence: 93%

Biomarker reproducibility in exhaled breath condensate collected with different condensers

Rosias¹,

Robroeks²,

Kester³

et al. 2008

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…EPO can be detected in the breath of healthy individuals (Schumann et al, 2006), suggesting its ubiquitous presence in the body Maiese et al, 2007c). In addition, it has been suggested that EPO may provide developmental cognitive support in humans with the recent observations that elevated EPO concentrations during infant maturation have been correlated with increased Mental Development Index scores (Bierer et al, 2006).…”

Section: Cellular Expression Of Epomentioning

confidence: 99%

Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies

Maiese

Chong

et al. 2008

Progress in Neurobiology

102

155

View full text Add to dashboard Cite

Given that erythropoietin (EPO) is no longer believed to have exclusive biological activity in the hematopoietic system, EPO is now considered to have applicability in a variety of nervous system disorders that can overlap with vascular disease, metabolic impairments, and immune system function. As a result, EPO may offer efficacy for a broad number of disorders that involve Alzheimer's disease, cardiac insufficiency, stroke, trauma, and diabetic complications. During a number of clinical conditions, EPO is robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. Yet, use of EPO is not without its considerations especially in light of frequent concerns that may compromise clinical care. Recent work has elucidated a number of novel cellular pathways governed by EPO that can open new avenues to avert deleterious effects of this agent and offer previously unrecognized perspectives for therapeutic strategies. Obtaining greater insight into the role of EPO in the nervous system and elucidating its unique cellular pathways may provide greater cellular viability not only in the nervous system but also throughout the body.

show abstract

“…The same is relevant for the other cytokines measured by immonuassays in native EBC samples. A similarly wide range of tumour necrosis factor (TNF)-a for healthy control subjects has been determined by the numerous research groups (0-27 pg?mL -1 ) [79,[82][83][84]. Most research groups studying TNF-a found this mediator in only a fraction of the samples (10-30%).…”

Section: Ebcmentioning

confidence: 99%

Exhaled biomarkers in lung cancer

Horváth

Lázár

Gyulai

et al. 2009

European Respiratory Journal

239

206

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death. Results of therapeutic interventions are particularly discouraging when the disease is discovered in an advanced stage. Early diagnosis is limited by the fact that the disease usually develops asymptomatically and available screening methods do not fulfil the requirements for reliable discrimination between patients with lung cancer and subjects not suffering from the disease. Breath sampling is completely noninvasive and provides a potentially useful approach to screening lung cancer. Exhaled biomarkers contain both volatile and nonvolatile molecules. The profile of volatile organic compounds is different in patients with lung cancer than in control subjects. In exhaled breath condensate, the proteomic profile of breath from cancer patients differs from that of healthy smokers. We reviewed the scientific evidence demonstrating that a unique chemical signature can be detected in the breath of patients with lung cancer and that the exhaled breath biomarker profile could aid clinical decision making.KEYWORDS: Biomarker, electronic nose, exhaled breath, exhaled breath condensate, lung cancer, smell L ung cancer is the leading cause of global cancer death in both males and females. According to the most recent projection of global mortality, by 2030 it will emerge as the third and the fifth leading cause of death in highand middle-income countries, respectively [1,2]. Figures on disease outcome measures are very discouraging as even with the most advanced treatment strategies ,86% of lung cancer patients die within 5 yrs of diagnosis. With early detection and treatment, however, the 5-yr survival rate improves dramatically from 20% in patients with stage III lung cancer to 70% in patients with stage I disease [3]. Researchers, therefore, have sought out screening tests to detect lung cancer in the earliest stages and several promising new approaches have been proposed for this purpose, such as computer-assisted image analysis of chest radiographs, spiral computed tomography (CT) scanning, PCR-based assays of sputum and fluorescence bronchoscopy [4][5][6][7].Breath chemical tests have a broad spectrum of applications ranging from the US Food and Drug Administration-approved exhaled nitric oxide fraction (FeNO) measurement to monitor the effect of anti-inflammatory treatment in asthma, to volatile organic compound (VOC) determination and nonvolatile biomarker profiling in the cooled breath sample called exhaled breath condensate (EBC) [8][9][10][11]. Being completely noninvasive, sampling of the breath allows clinicians and researchers to assess different body functions in a flexible manner. Breath collection can be performed even in very severe patients and also repeated within short intervals. Therefore, breath testing is considered to be a potentially ideal candidate for screening purposes. Besides widely known constituents such as nitrogen, oxygen, carbon dioxide, inert gases and water vapour, exhaled breath also consists of thousands of volatile and nonv...

show abstract

Detection of Erythropoietin in Exhaled Breath Condensate of Nonhypoxic Subjects Using a Multiplex Bead Array

Cited by 28 publications

References 31 publications

Biomarker reproducibility in exhaled breath condensate collected with different condensers

Biomarker reproducibility in exhaled breath condensate collected with different condensers

Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies

Exhaled biomarkers in lung cancer

Contact Info

Product

Resources

About